Compare Agilent Technologies Inc (A) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs JPMorgan Chase & Co — how do they compare? Agilent Technologies Inc trades at $149.35 (market cap $42.00B), while JPMorgan Chase & Co trades at $362.04 (market cap $956.39B). The key difference: JPMorgan Chase & Co is far larger — about 22.8× Agilent Technologies Inc's market cap, and JPMorgan Chase & Co pays the higher dividend (1.67%). Which is the better fit depends on your goals.
| A | JPM | |
|---|---|---|
Market Cap | $42.00B | $956.39B |
Sector | Health | Financials |
52-Week High | $157.20 | $359.79 |
52-Week Low | $110.24 | $282.84 |
Enterprise Value | $43.55B | — |
Dividend Yield | 0.69% | 1.67% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $145.97, up 3.28% in the last session, with a bullish technical outlook from moving averages but overbought RSI levels. The company reported strong Q1 2026 earnings, beating estimates with EPS of $1.49, and maintains solid profitability with a net income margin of 19.55%. Recent developments include FDA and EU approvals for diagnostic assays and the acquisition of Biocare Medical, enhancing its healthcare portfolio.
The stock offers upside to the consensus price target of $154.90, supported by analyst optimism (77.5% buy ratings), but high valuation ratios like a P/E of 146.56 pose risks. Investors should monitor execution of growth initiatives and competitive pressures in the life sciences sector, with earnings on August 26, 2026, as a key catalyst.
JPMorgan Chase (JPM) trades at $359.79, up 0.63% today, near its pivot point of $359. The stock shows a bullish technical trend with moving averages supporting upside. Recent earnings beat expectations in Q1 and Q2 2026, with Q1 EPS of $5.94 versus $5.47 expected, though Q4 2025 missed. Revenue grew to $181.85B in 2025, and net income margin stands at 33.38%. A $1.50 dividend is scheduled for payment on July 31, 2026.
JPMorgan's outlook remains positive with analyst consensus at 'Moderate Buy' and a $374.18 price target, offering ~4% upside. Strong ROE of 18.43% and institutional accumulation highlight confidence. Risks include geopolitical tensions affecting oil markets and cybersecurity threats from AI, as noted in recent news. The stock's valuation at P/E 15.42 is reasonable relative to earnings growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
